Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
Q3 2024 vs. Q2 2024
How the institutions holding Damora Therapeutics, Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 22 | 1 | 10 | −11 |
| SharesConverted for a 1-for-25 split | 161.5K | 848.2 | 128.6K | −32.0K (−19.9%) |
| Value | $1.91M | $10.1K | $1.56M | −$341.1K (−17.9%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (3)
Institutions that held Damora Therapeutics, Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 5,099 | $62.0K | 0.00% |
| BlackRock, Inc. | 490 | $5.95K | 0.00% |
| Danske Bank A/S | 7 | $85 | 0.00% |
Sold out (14)
Institutions that held Damora Therapeutics, Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Vanguard Group Inc | 221,200 | $104.9K |
| Geode Capital Management, LLC | 214,134 | $101.6K |
| Susquehanna International Group, LLP | 168,352 | $79.8K |
| Citadel Advisors LLC | 128,584 | $61.0K |
| State Street Corp | 44,906 | $21.3K |
| Northern Trust Corp | 35,639 | $16.9K |
| Two Sigma Securities, LLC | 27,136 | $12.9K |
| Summit Trail Advisors, LLC | 25,000 | $11.9K |
| Commonwealth Equity Services, LLC | 16,027 | $8.00K |
| Virtu Financial LLC | 14,678 | $7.00K |
| JPMorgan Chase & Co | 2,962 | $1.41K |
| Spire Wealth Management | 2,018 | $949 |
| Royal Bank of Canada | 193 | $0 |
| Simplex Trading, LLC | 647 | $0 |
Not filed for Q3 2024 yet (1)
Institutions that held Damora Therapeutics, Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 21,205 | $10.1K |